Patents Examined by Emily Bernhardt
  • Patent number: 10414767
    Abstract: Deuterated quinazolinone compounds and pharmaceutical compositions containing such compounds are provided. In particular, deuterated quinazolinone compounds of formula (I) are provided, as well as pharmaceutical compositions containing such compounds or crystal form, pharmaceutically acceptable salts, hydrates or solvates thereof. The deuterated quinazolinone compounds of formula (I) can be used for treating and/or preventing PI3K kinase-associated diseases, such as cancer, cell proliferative diseases and the like.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: September 17, 2019
    Assignee: Suzhou Zelgen Biopharmaceuticals Co., Ltd.
    Inventors: Binhua Lv, Chengwei Li
  • Patent number: 10413546
    Abstract: A medicament for prophylactic and/or therapeutic treatment of dementia, which comprises a compound represented by the formula (I) having a xanthine oxidase inhibitory action as an active ingredient.
    Type: Grant
    Filed: February 23, 2016
    Date of Patent: September 17, 2019
    Assignees: NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY, NIPPON MEDICAL SCHOOL FOUNDATION, NIPPON CHEMIPHAR CO., LTD.
    Inventors: Takeshi Nishino, Shinsuke Kato, Masako Kato, Hidenori Suzuki, Ken Okamoto
  • Patent number: 10414731
    Abstract: The invention relates to substituted oxopyridine derivatives of formula (I) and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.
    Type: Grant
    Filed: September 22, 2015
    Date of Patent: September 17, 2019
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Susanne Röhrig, Alexander Hillisch, Stefan Heitmeier, Martina Victoria Schmidt, Karl-Heinz Schlemmer, Adrian Tersteegen, Henrik Teller
  • Patent number: 10406166
    Abstract: The invention relates to compounds of formula (I), and pharmaceutical uses thereof. Particular aspects of the invention relate to methods of synthesizing the compounds and the use of those compounds in treating, ameliorating, or preventing a microbial infection.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: September 10, 2019
    Assignee: The University of Durham
    Inventors: Stuart Cockerill, Jonathan Harburn
  • Patent number: 10407409
    Abstract: The present invention provides compounds of the formula: which are useful as inhibitors of PHD, pharmaceutical compositions thereof, methods for treatment of conditions associated with HIF, processes for making the compounds and intermediates thereof.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: September 10, 2019
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Jason W. Brown, Melinda Davis, Anthony Ivetac, Benjamin Jones, Andre A. Kiryanov, Jon Kuehler, Marion Lanier, Joanne Miura, Sean Murphy, Xiaolun Wang
  • Patent number: 10407415
    Abstract: An object of the present invention is to provide a compound that can be used as a more superior therapeutic agent for central nervous system diseases. The present invention provides a dihydrate of 7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one or of a salt thereof, and a process for producing the same.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: September 10, 2019
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Hiroshi Yamashita, Tetsuya Sato, Takuya Minowa, Yusuke Hoshika, Hidekazu Toyofuku, Tetsuya Yamaguchi, Masahiro Sota, Shuuji Kawano, Takayuki Nakamura, Ryohei Eto, Takuma Ikebuchi, Kei Moriyama, Nobuaki Ito
  • Patent number: 10407446
    Abstract: The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where R1 and R2 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent DNA-PK mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating DNA-PK mediated disease, including cancer, using such compounds and salts.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: September 10, 2019
    Assignees: AstraZeneca AB, Cancer Research Technology Limited
    Inventors: Maurice Raymond Verschoyle Finlay, Frederick Woolf Goldberg, Attilla Kuan Tsuei Ting
  • Patent number: 10407432
    Abstract: The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R1, R2 and n have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use as anti-proliferative and/or cell-killing agents.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: September 10, 2019
    Assignee: AstraZeneca AB
    Inventors: Robert Hugh Bradbury, Alfred Arthur Rabow, Michael James Waring, James Francis McCabe, Steven Christopher Glossop, Arshed Mahmood, Zoe Ann Cotter
  • Patent number: 10399949
    Abstract: A problem of the present invention is to provide a new compound which has NK1 receptor antagonist activity, and thus is useful for the prevention or treatment of cancer-chemotherapy-induced nausea and vomiting. A compound represented by the formula (I): wherein W represents a fluorine atom and the like, ring A represents a cycloalkyl and the like, X1 represents CH or N, R represents methyl and the like, Y represents 0 to 2, U1, U2 and U3 each independently represents a single bond and the like, or a pharmaceutically acceptable salt thereof. The compounds of the present invention or pharmaceutically acceptable salts thereof have an excellent NK1 receptor antagonist activity, and thus are also useful as an agent for the prevention or treatment of cancer-chemotherapy-induced nausea and vomiting.
    Type: Grant
    Filed: December 6, 2016
    Date of Patent: September 3, 2019
    Assignee: KISSEI PHARMACEUTICAL CO., LTD.
    Inventors: Takashi Miyagi, Masahiro Kobayashi, Toshihiro Nishimura
  • Patent number: 10399988
    Abstract: The present invention relates to 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical compositions containing the same, wherein the 4-aminopyrazolo[3,4-d]pyrimidinylazabicyclo derivatives and pharmaceutical compositions containing them not only have BTK inhibitory activity but also has remarkably high selectivity for the inhibitory activity of BTK vs. ITK, and thereby can be usefully used for the prevention or treatment of autoimmune diseases or cancers as BTK inhibitors.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: September 3, 2019
    Assignee: Daewoong Pharmaceutical Co., Ltd.
    Inventors: Youn-Jung Yoon, Jung-Eun Park, Yeon-Jung Park, Min-June Shim, Keuk-Chan Bang, Joon-Seok Park
  • Patent number: 10399945
    Abstract: The present invention aims to provide a compound having a TrkA inhibitory action, a pharmaceutically acceptable salt thereof, or a solvate thereof, a pharmaceutical composition containing the same as an active ingredient, and a preventive and/or therapeutic agent for medicinal use, in particular for a disease in which TrkA in involved (pain, cancers, inflammation/inflammatory diseases, allergic diseases, skin diseases, neurodegenerative diseases, infectious diseases, Sjogren's syndrome, endometriosis, renal diseases, osteoporosis, and the like).
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: September 3, 2019
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Fumihiko Saitoh, Hiroshi Nagasue
  • Patent number: 10399980
    Abstract: The application relates to inhibitors of USP1 useful in the treatment of cancers, and other USP1 associated diseases and disorders, having the Formula: where R1, R2, R3, R3?, R4, R5, X1, X2, X3, X4, and n are described herein.
    Type: Grant
    Filed: August 1, 2018
    Date of Patent: September 3, 2019
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Alexandre Joseph Buckmelter, Stephanos Ioannidis, Bruce Follows, Gary Gustafson, Minghua Wang, Justin A. Caravella, Zhongguo Wang, Edward L. Fritzen, Jian Lin
  • Patent number: 10399982
    Abstract: Compounds, compositions and methods are described for inhibiting the TRPC5 ion channel and disorders related to TRPC5.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: September 3, 2019
    Assignee: Hydra Biosciences, Inc.
    Inventors: Bertrand L. Chenard, Randall J. Gallaschun
  • Patent number: 10392397
    Abstract: Pharmaceutical compounds, compositions, and methods are presented in which various heterocyclic thiosemicarbazone derivatives are prepared. Contemplated compounds will be suitable to inhibit or reduce cellular growth or proliferation and are thus beneficial in the manufacture of drugs to treat neoplastic diseases.
    Type: Grant
    Filed: August 8, 2016
    Date of Patent: August 27, 2019
    Assignees: NantBio, Inc., Nant Holdings IP, LLC
    Inventors: Chunlin Tao, Qinwei Wang, Patrick Soon-Shiong
  • Patent number: 10392347
    Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: August 27, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Soong-Hoon Kim, Hannguang J. Chao, Heather Finlay, Ji Jiang, James A. Johnson, R. Michael Lawrence, Michael C. Myers, Monique Phillips, George O. Tora, Wei Meng
  • Patent number: 10392353
    Abstract: Disclosed herein is a novel process for preparing substituted quinazoline compounds of formula (I) using a hydrogen bonding catalyst.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: August 27, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Cheol K. Chung, Guy R. Humphrey, Zhijian Liu, Mark McLaughlin, Yingju Xu, Younong Yu
  • Patent number: 10388903
    Abstract: An organic electroluminescent element having high durability can be provided by using a compound represented by the following general formula (1), wherein: Z1 to Z4 each represent a carbon atom or a nitrogen atom; A1 represents an atomic group which is combined with Z1 and a nitrogen atom to form a 5- or 6-membered hetero ring; B1 represents an atomic group which is combined with Z2 and a carbon atom to form a 5- or 6-membered ring; C1 represents an atomic group which is combined with Z3 and a nitrogen atom to form a 5- or 6-membered hetero ring; D1 represents an atomic group which is combined with Z4 and a carbon atom to form a 5- or 6-membered ring; n represents 1 or 2; L represents a single bond or a linking group; and G represents a fused ring with 3 or more rings.
    Type: Grant
    Filed: November 14, 2012
    Date of Patent: August 20, 2019
    Assignee: UDC Ireland Limited
    Inventors: Yosuke Yamamoto, Kousuke Watanabe, Yuichiro Itai
  • Patent number: 10383866
    Abstract: The present invention provides compounds of Formula (I), and pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav1.7. The compounds are useful for the treatment of diseases associated with the activity of sodium channels such as pain disorders, cough, and itch. Also provided are pharmaceutical compositions containing compounds of the present invention.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: August 20, 2019
    Assignee: AMGEN INC.
    Inventors: Matthew Weiss, Thomas Dineen, Benjamin C. Milgram
  • Patent number: 10370376
    Abstract: The present invention relates to an amorphous form of Idelalisib and its methods of preparation. Using a Cu-K? radiation, the X-ray powder diffraction (XRPD) pattern does not contain sharp diffraction peaks at a diffraction angle expressed in degrees 2?, and the X-ray powder diffraction pattern is shown in FIG. 1. The present invention also provides a preparation method for the amorphous form of Idelalisib. The amorphous form of Idelalisib of the present invention increases the solubility of Idelalisib and improves bioavailability of the drug product. As compared to the existing crystalline forms of Idelalisib, its solubility increases significantly, which improves body's absorption of the drug and makes it more efficacious in the clinical therapeutic treatment of diseases. Under the stress test conditions, the amorphous material can maintain good physical and chemical stabilities. The preparation method of amorphous Idelalisib according to the present invention is simple to operate and easy to implement.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: August 6, 2019
    Assignee: Alnova Pharmaceuticals, Ltd.
    Inventors: Xini Zhang, Zhigang Xiong, Tao Hu
  • Patent number: 10370340
    Abstract: This invention concerns HIV replication inhibitors of formula the N-oxides, the pharmaceutically acceptable addition salts, the quaternary amines and the stereochemically isomeric forms thereof, wherein the ring containing -a1=a2-a3=a4- and -b1=b2-b3=b4- represents phenyl, pyridyl, pyrimidinyl, pirazinyl, pyridazinyl; n is 0 to 5; m is 1 to 4; R1 is hydrogen; aryl; formyl; C1-6alkylcarbonyl; C1-6alkyl; C1-6alkyloxycarbonyl; substituted C1-6alkyl, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonyloxy; substituted C1-6alkyloxyC1-6alkylcarbonyl; R2 is hydroxy, halo, optionally substituted C1-6alkyl, C3-7cycloalkyl, optionally substituted C2-6alkenyl, optionally substituted C2-6alkynyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, —S(?O)pR6, —NH—S(?O)pR6, —C(?O)R6, —NHC(?O)H, —C(?O)NHNH2, —NHC(?O)R6, —C(?NH)R6 or a 5-membered heterocycle; X1 is —NR5—, —NH—NH—, —N?N—, —O—, —C(?O)—, C1-4alkanediyl,
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: August 6, 2019
    Assignee: Janssen Pharmaceutica NV
    Inventors: Jérôme Emile Georges Guillemont, Patrice Palandjian, Marc René de Jonge, Lucien Maria Henricus Koymans, Hendrik Maarten Vinkers, Frederik Frans Desiré Daeyaert, Jan Heeres, Koen Jeanne Alfons Van Aken, Paulus Joannes Lewi, Paul Adriaan Jan Janssen